

1 **Title:** Real-World Performance of the Alinity m STI Assay for the simultaneous
2 detection of Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma genitalium,
3 and Trichomonas vaginalis in Clinical Specimens at a Large Tertiary Hospital
4 System in the United States

5

6 Karen C. Rexroth M,ASCP^{1,*} and Joshua Kostera, Ph.D.²

7

8 ¹ Department of Veterans Affairs Medical Center, Washington DC, USA

9 ² Abbott Molecular Diagnostics, Des Plaines, IL, USA

10

11 ***Corresponding author:** Joshua Kostera

12 Phone 312.576.8696

13 Email: Joshua.Kostera@abbott.com

14

15 **Word count summary:** 30

16 **Word count abstract:** 250

17 **Word count text:** 2992

18 **Number of references:** 24

19 **Number of figures:** 3

20 **Number of tables:** 5

21

22 **Conflicts of interest:** Joshua Kostera is an employee of Abbott Laboratories.

23 **Sources of support:** Abbott Molecular provided the Alinity m STI reagents for the
24 study.

25 **Summary**

26 Evaluation of the Alinity m STI assay in a large US hospital system identified a
27 higher prevalence of trichomonas and mycoplasma infections than chlamydia and
28 gonorrhoeae infections in urogenital specimens.

29

30 **KEY MESSAGES**

31 **What is already known on this topic**

- 32 • Mycoplasma genitalium and Trichomonas vaginalis are sexually transmitted
33 infections, however, global prevalence data vary between geographical regions, as
34 these sexually transmitted infections are not included in routine screening.

35 **What this study adds**

- 36 • This study aimed at assessing Trichomonas and Mycoplasma prevalence and
37 association with a positive Chlamydia and/or Gonorrhoeae result.

38 **How this study might affect research, practice, or policy**

- 39 • Including Mycoplasma genitalium and Trichomonas vaginalis testing in a routine
40 screening STI diagnostic algorithm, with cost-effective and accurate multiplex assays
41 can improve diagnosis to initiation of appropriate treatment.

42 **Abstract**

43 **Background:** In the US, sexually transmitted infections (STI) are reported for
44 Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) but not Trichomonas
45 vaginalis (TV) and Mycoplasma genitalium (MG). TV and MG surveillance data in the
46 US remains inadequate. We evaluated the performance of the fully automated, multi-
47 plex PCR-based Alinity m STI assay, to simultaneously detect CT, NG, TV, and MG,
48 at a large Veterans Affairs hospital system.

49 **Methods:** 260 urine, urogenital, and extragenital clinical specimens were tested with
50 the Alinity m STI assay and the results were compared to those from the Abbott
51 RealTime CT/NG assay in our lab and TV and MG assays run at an external
52 reference laboratory.

53 **Results:** Alinity m STI assay results for urine specimens had an overall percent
54 agreement (OPA) with the RealTime comparator assay of 187/187 (100.0%) for CT
55 and 186/187 (99.5%) for NG. For 20 rectal specimens, the OPA for CT was 95% and
56 for NG was 100%; for 13 oral specimens, OPA was 100% for CT and 92.3% for NG.
57 Of the urine specimens sent for TV and MG testing, 100% agreement was observed
58 between the Alinity m STI assay and TV (n=104) and MG (n=30) comparator assay
59 results.

60 **Conclusions:** The Alinity m STI assay is an easy-to-use, sensitive and specific
61 assay that allows high-throughput testing for common and undertested STI
62 pathogens to facilitate surveillance efforts.

63

64 **Key words:** sexually transmitted infection, multi-plex assay, cellular control, NAAT,
65 diagnostic assay

66 **Introduction**

67 In the United States, approximately 2.5 million STIs were diagnosed in 2021,^{1,2}
68 despite recent reports declaring that Americans are having less sex in the pandemic
69 era.^{3,4} A recent report from the World Health Organization (WHO) estimated that
70 there were 374 million new STIs globally in 2020, with more than 1 million people
71 infected each day with 1 of the 4 most common pathogens: *Chlamydia trachomatis*
72 (CT; 129 million), *Neisseria gonorrhoeae* (NG; 82 million), syphilis (7.1 million), and
73 *Trichomonas vaginalis* (TV; 156 million).⁵ The well-characterized bacterial pathogens
74 CT and NG, as well as TV and *Mycoplasma genitalium* (MG) are recognized STI
75 pathogens;⁵⁻⁷ however, TV and MG are not considered reportable by CDC.⁸
76 Undiagnosed and untreated STIs have significant and lifelong reproductive and non-
77 reproductive health consequences, and can increase the risk of acquiring or
78 transmitting HIV.⁸⁻¹⁰ Accurate diagnosis of STIs is necessary to interrupt
79 transmission pathways and initiate timely and appropriate treatment to improve long-
80 term health outcomes and avoid multidrug resistance.^{8,11-13}

81

82 Diagnosis of STIs can be challenging, as the pathogens cause overlapping
83 symptoms or subclinical symptoms that may be misdiagnosed or overlooked.
84 Current guidelines recommend the use of nucleic acid amplification testing (NAAT)
85 to screen for the reportable pathogens, CT and NG, and help reduce transmission
86 and guide precision treatment.^{14,15} NAAT-based surveillance programs for TV and
87 MG would allow additional detection of subclinical or asymptomatic infections and
88 further hone treatment algorithms.^{8,16,17}

89

90 To reduce the time to diagnosis and detect multiple pathogens in a single specimen,

91 the Alinity m STI assay is a qualitative multiplex PCR-based test for the
92 simultaneous detection of CT ribosomal RNA sequences, NG DNA sequences, TV
93 ribosomal RNA sequences, and MG ribosomal RNA sequences extracted from
94 endocervical swab, vaginal swab, male and female urine, oropharyngeal swab, and
95 rectal swab specimens, and gynecological specimens preserved in ThinPrep
96 PreservCyt[®] Solution.¹⁸ The assay also amplifies and detects an endogenous human
97 DNA sequence (cellular control, CC) and an internal control (IC) in every specimen
98 to confirm specimen adequacy and process validity, respectively. The reporting
99 structure of the assay releases results for any combination of CT, NG, TV, and MG
100 along with the IC and CC results for each specimen.

101

102 In our study, we evaluated the real-world clinical performance of the Alinity m STI
103 assay compared to other commercially available molecular assay platforms for
104 detection of CT, NG, TV, and MG, as well as its utility for surveillance of TV and MG
105 infection, at the Washington DC Veterans Affairs Medical Center (DC VAMC), a
106 large tertiary hospital in the US. DC VAMC serves veterans in the District of
107 Columbia and surrounding suburbs, Maryland, and West Virginia, which has an
108 estimated veteran population of 765,000. The DC VAMC is an acute care hospital
109 that includes 7 community-based outpatient clinics, a women's clinic, infectious
110 diseases clinic, and an emergency department; specimens included in this study
111 were acquired at each of these locations. As Washington DC has the fifth highest
112 STI rate in the US,² the DC VAMC is a favorable site for not only evaluating the
113 performance of the Alinity m STI assay but also examining the cross-sectional
114 prevalence of detected STIs compared to the latest statistics released by the CDC.

115

116 **Methods**

117 The study included 3 objectives. The first was to perform an observed sensitivity
118 assessment using standard biological reference materials from a third-party
119 manufacturer (Exact Diagnostics, Fort Worth, TX) to evaluate the sensitivity of the
120 assay. The second objective was to conduct a clinical comparative evaluation in
121 which specimens were tested with the Alinity m STI assay and other commercially
122 available STI assays to determine result agreement. The third objective was an ad
123 hoc stability study evaluating individual neat urine specimens confirmed positive with
124 a STI pathogen to determine specimen integrity for up to 7 days in cold storage,
125 either refrigerated or frozen, prior to testing with the Alinity m STI assay. All statistical
126 analyses were completed using SAS version 9.3 or higher, or Microsoft Excel
127 version 2108.

128

129 ***Observed sensitivity assessment***

130 To evaluate the sensitivity of the Alinity m STI assay for each of the 4 pathogens
131 (CT, NG, TV, MG), biological reference material (Exact Diagnostics) for each
132 organism was used. Materials were stored and handled according to the labeling
133 instructions provided by the manufacturer. The material contains whole intact
134 biological organism in a synthetic matrix and contains preservative that is value
135 assigned using digital droplet PCR with assigned units in copies/mL. Alinity m multi-
136 Collect Specimen Collection Kit stabilization buffer was used to make up a bulk
137 diluent, which was then used to prepare multiple panels where the reference material
138 was spiked to create diluted titers for each of the 4 pathogens. A range-finding study
139 was performed for each of the pathogens to determine the observed sensitivity of the

140 assay. This was followed by testing 10 replicates at the 2 lowest range-finding titer
141 levels at which the assay could detect 95% or greater of replicates.

142

143 ***Clinical comparative evaluation***

144 A total of 260 deidentified adult urogenital and extragenital remnant clinical
145 specimens were included in this study (Figure 1), which was determined to be
146 exempt by the DC VAMC IRB. Specimens were acquired after obtaining informed
147 consent from consecutive inpatients and outpatients at the DC VAMC. Specimens
148 were collected in accordance with institutional standard practices and procedures as
149 part of routine patient care and consisted of male and female urine and rectal,
150 oropharyngeal, vaginal, and endocervical swabs. Additional gynecological
151 specimens acquired for the study were collected in ThinPrep PreservCyt[®] and stored
152 according to the manufacturer instructions.

153

154 Clinical swab specimens included in the study were dual collected using the Abbott
155 multi-Collect Specimen Collection Kit (Abbott Kit) and the Alinity m multi-Collect
156 Specimen Collection Kit (Alinity Kit). The 2 collection kits are intended for the
157 collection and transportation of male and female urine specimens, endocervical
158 swab specimens, vaginal swab specimens, oropharyngeal swab specimens, and
159 rectal swab specimens to stabilize nucleic acid for testing with the Alinity m STI
160 assay. Urine specimens sent to the laboratory were split between the 2 collection
161 kits, and approximately 2 mL of specimen was aseptically transferred to the
162 collection kit tube according to the manufacturer's instructions. All specimens once
163 added to the respective collection devices were stored refrigerated at 2-8°C for up to
164 14 days or frozen at -20°C for up to 60 days. The Alinity kit specimens were tested

165 with the Alinity m STI assay and Abbott kit specimens were tested with the Abbott
166 RealTime CT/NG assay (Abbott Laboratories). The clinical evaluation was conducted
167 using 3 lots of amplification reagents, controls, and bulk specimen extraction
168 reagents. Alinity m STI results for CT and NG were compared to the Abbott
169 RealTime CT/NG assay results. Alinity m STI results for TV and MG were compared
170 to those from specimens sent to an external reference laboratory service (Labcorp,
171 Burlington, NC). Specimens that were sent to the external reference laboratory
172 service were also collected in the Aptima Transport tube. The external laboratory
173 service tests TV using TMA technology and MG using the Sureswab[®]
174 Mycoplasma/Ureaplasma Panel. Extragenital specimen testing was previously self-
175 validated for use with the Abbott RealTime CT/NG assay.

176

177 ***Urine specimen stability assessment***

178 To evaluate neat urine specimen stability prior to processing, patients followed the
179 clean catch urine collection procedure using a sterile collection container. Specimens
180 that were individually identified as positive for CT, NG, TV, and MG were split into 2
181 aliquots. One aliquot was refrigerated at 4°C and the other was aliquoted into 4
182 transport tubes containing no preservative buffer and capped. These were stored at
183 frozen at -20°C. Individual specimen aliquot tubes were used to mitigate the freeze-
184 thaw impact on stability of the specimens; the impact of freeze-thaw cycles on
185 specimen stability was not assessed in this investigation. The stability testing
186 schedule included test points on day 1, 3, 5, and 7 to simulate a delayed specimen
187 testing scenario. The cycle number (CN) for each specimen was recorded for each
188 test point to determine the impact of storage temperature and time on Alinity m STI
189 assay performance.

190

191 **Results**

192 ***Alinity m STI is sensitive for detection of all 4 pathogens***

193 Prior to testing clinical specimens, an observed sensitivity assessment was
194 performed to determine the overall sensitivity of the Alinity m STI assay. The
195 sensitivity assessment was conducted using 1 lot of amplification reagents, controls,
196 and bulk specimen extraction reagents. An initial range finding experiment was
197 completed (Supplemental Table s1), followed by a final sensitivity confirmation. The
198 limit of detection of the Alinity m STI assay was 5 copies/mL for CT, 50 copies/mL for
199 NG, 50 copies/mL for TV, and 900 copies/mL for MG. Table 1 shows the final
200 observed sensitivity results as well as calculated conversion estimates to units
201 presented in the Alinity m STI assay package insert.¹⁸

202

203 ***Alinity m STI assays produce comparable clinical results across specimen*** 204 ***types***

205 For clinical specimens, Alinity m STI results for CT and NG were compared to Abbott
206 RealTime CT/NG assay results; Alinity m STI results for TV and MG results were
207 compared to those received from an external reference laboratory service for NAAT
208 testing. Reflecting the current state of STI testing in the US and the real-world design
209 application of the study, not all specimens included in our evaluation were ordered
210 for TV and MG testing. Based on the patient risk profile and clinical presentation,
211 specimens were ordered and sent out for TV and MG testing at the direction of the
212 patient provider. For the subset of specimens for which comparator testing results
213 were available, Alinity m STI results were compared to external assay testing for 104
214 specimens for TV and 30 specimens for MG.

215

216 Using the Abbott RealTime CT/NG assay and external laboratory service tests for TV
217 and MG as a reference, the Alinity m STI assay produced an OPA $\geq 92.3\%$ for
218 extragenital specimens and $\geq 99.5\%$ for urine specimens. The clinical OPA, NPA,
219 and PPA for the Alinity m STI assay across sample types are presented in Table 2.

220

221 Although the sample size was smaller ($n=33$) for extragenital specimens than for
222 urogenital specimens ($n=227$), the observed prevalence for CT (18.2%) and NG
223 (27.3%) in extragenital specimens was much higher than the mono-infection
224 urogenital prevalence for CT (5.0%) and NG (5.0%). Co-infections were also
225 detected in the study cohort; 9.0% of rectal specimens and 1.0% of urine specimens
226 were positive for both CT and NG with the Alinity m STI assay and correlated 100%
227 with the comparator assay. One (0.20%) urine specimen was positive for CT and MG
228 with the Alinity m STI assay, with the CT result confirmed on the Abbott RealTime
229 CT/NG assay (this specimen was not ordered for MG testing). One (3.0%) rectal
230 specimen was positive for NG and MG with the Alinity m STI assay, with the NG
231 result confirmed on the Abbott RealTime CT/NG assay (this specimen was not
232 ordered for MG testing).

233

234 In the clinical specimen evaluation data set, 3 discrepant results were observed
235 between the Alinity m STI assay and reference tests (Abbott RealTime CT/NG or
236 external laboratory services TV and MG tests). The 3 discrepant results were 1
237 urine and 1 oral specimen discrepant for NG and 1 rectal specimen discrepant for
238 CT results. All 3 specimens had very high CNs, indicating very low levels of target
239 pathogen. All specimens generated valid results on the Alinity m STI assay (valid IC

240 and CC results) with no inhibition observed, including for extragenital rectal and
241 oropharyngeal swab specimen types (data not shown).

242

243 The number and sources of clinical specimens included in this study are summarized
244 in Table 3 along with the Alinity m STI assay testing results. Twenty-nine specimens
245 in ThinPrep PreservCyt[®] were tested with the Alinity m STI assay; however, all
246 specimens were negative for CT, NG, TV, and MG. Of note, the combined total
247 prevalence of non-reportable pathogens TV and MG (n=31) was observed to be
248 15.2% in the urogenital study population compared to the combined prevalence of
249 CT and NG (n=25), which was observed to be 10.1%.

250

251 ***Urine specimens are stable for up to 7 days at 4°C or -20°C***

252 The objective of this study component was to investigate potential influence of
253 storage temperature and time on the stability of neat urine specimens, based on the
254 CN values from the Alinity m STI assay.

255

256 All CN data points for both refrigerated and frozen storage conditions were within 2
257 SD of the average CN for all specimens in the study, indicating that there were no
258 statistically significant data points that could suggest significant degradation of the
259 specimens, data shown in supplemental Table s2.

260

261

262

263

264

265 **Discussion**

266 Our clinical findings are consistent with those of another recent study²⁰ comparing
267 the clinical performance of the Alinity m STI assay with Abbott RealTime CT/NG
268 assay, which showed similar agreement for detecting CT, NG, and MG in patient
269 specimens. A separate multicenter study also showed high correlations between the
270 Alinity m STI assay and various comparator assays.²¹ In our study, across all
271 specimen types in the entire study cohort, 25.0% (n=65/260) of patient specimens
272 were found to have either a mono or co-infection STI. STIs that are not accurately
273 diagnosed will continue to challenge public health causing significant and serious
274 long-term health consequences for patients.

275

276 Historically, MG has not been routinely tested at DC VAMC; as all 4 pathogens can
277 be simultaneously detected by the Alinity m STI assay, it is notable that MG was
278 observed to have the highest positivity rate compared to the other STI pathogens in
279 our specimen cohort. 12.6% of male urine specimens were positive for MG,
280 compared to 8.4% for CT and 7.7% for NG. For female urine specimens in our study,
281 MG was detected in 6.8% of specimens, also higher than that detected for CT
282 (2.27%), and no cases of NG were detected. Although 187 urogenital specimens
283 were not ordered for MG testing, 16 (~10%) of those were positive for MG and
284 negative for CT, NG, and TV on the Alinity m STI assay. All CT and NG results were
285 confirmed with comparator testing and 109 out of the 260 specimens were ordered
286 and confirmed for TV with comparator testing. MG infections are generally
287 asymptomatic in both men and women, contributing up to 35% of non-chlamydial
288 non-gonococcal urethritis in men and linked to cervicitis and pelvic inflammatory
289 disease in women.⁶ Clinical treatment failures and antimicrobial-resistant MG are a

290 significant concern, and rising incidence rates of unknown magnitude have
291 complicated the clinical management of this infection. The consequences of an
292 undiagnosed and untreated MG infection can be severe; our findings support the
293 need for STI multi-plex testing to include MG.

294

295 Globally, TV is the most common, curable non-viral STI that is often associated with
296 serious health consequences including preterm birth, low-birthweight infants, and
297 infertility, as well as increasing the risk for acquisition and transmission of human
298 immunodeficiency virus (HIV).^{5,8} The epidemiology of TV in men is less delineated
299 than for women, for the male urine specimens included in our study, we observed a
300 4.9% positivity rate for TV. Risk factors for TV in women include older age, race,
301 impoverished socioeconomic status, and multiple sexual partners.¹⁰ In our study,
302 4.5% of female urine specimens were positive for TV. At present, neither TV nor MG
303 meet all the criteria for confirmed cases to be reported to the CDC, including for
304 women who are pregnant.

305

306 Our study findings support the use of NAATs for testing and surveillance of STI
307 pathogens such as MG and TV. Simultaneous detection of the 4 major STI
308 pathogens by the Alinity m STI assay would simplify the implementation of MG/TV
309 surveillance programs in health systems that already report NG and CT infections.
310 TV and MG surveillance programs can lead to evidence-driven changes in the STI
311 diagnostic algorithm, with cost-effective and accurate multiplex assays moving
312 patients quickly from diagnosis to initiation of appropriate treatment.

313

314 Infections at extragenital sites are typically asymptomatic and latent, making clinical
315 diagnosis challenging in the absence of a sensitive and specific molecular assay.
316 Extragenital specimens were included in our study to evaluate the performance of
317 the Alinity m STI assay with oropharyngeal and rectal swabs. Extragenital testing is
318 not always part of routine STI screening algorithms, although recent studies have
319 highlighted the STI incidence rate at the oropharynx and rectum, leading to a shift in
320 practice to include screening of extragenital sites.¹⁹ In total, 33 extragenital
321 specimens were submitted for testing in our study. Four out of 13 oropharyngeal
322 specimens (30.8%) were positive for NG. Three out of 20 rectal specimens (15.0%)
323 were positive for both CT and NG, 5 (25.0%) were positive for NG, 4 (20.0%) were
324 positive for CT, and 1 (5.0%) was positive for both NG and MG. The extragenital
325 specimens included in this study were primarily collected from male patients (n=32),
326 with only 1 extragenital specimen from a female patient. Overall, men who have sex
327 with men (MSM) demonstrate a higher prevalence of extragenital infection compared
328 to women and men who have sex with women,²² however, extragenital STI testing
329 should be considered for both men and women.²² An increased risk of HIV
330 acquisition is a potential consequence of untreated extragenital infections, which can
331 serve as a potential reservoir for transmission specifically in patients with repeat
332 gonococcal and chlamydial rectal infections.²³ Surveilling the frequency of STI will
333 inform how trends in screening programs change over time as HIV PrEP access
334 expands and STI screening programs become more widely adopted among PrEP
335 users.²²

336

337 Staffing shortages and specimen transport logistical challenges can introduce unique
338 impediments that reduce laboratory testing efficiency. Patient specimen hold times

339 can vary prior to processing into the appropriate collection device, tube, or media
340 that is utilized with the testing methodology or system to analyze the specimen.
341 Furthermore, current guidelines in the literature are contradictory for urine storage
342 temperatures and duration prior to analysis. The findings from our assessment suggest
343 that correctly collected neat urine specimens intended for STI testing that cannot be
344 processed immediately maintain integrity when stored refrigerated or frozen for up to 7 days
345 prior to processing. Differences in bio-metabolic profiles that can impact specimen integrity
346 were not examined.

347

348

349 **Acknowledgements**

350 The authors would like to thank Yan Zhang, PhD, for assistance with the statistical
351 analysis. Stacey Tobin, PhD, provided editorial support for manuscript preparation,
352 with compensation from Abbott Laboratories.

353

354 **References**

- 355 1. Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually Transmitted Infections
356 Among US Women and Men: Prevalence and Incidence Estimates, 2018.
357 *Sexually Transmitted Diseases*. 2021;48(4):208-214.
358 doi:10.1097/olq.0000000000001355
- 359 2. Centers for Disease Control and Prevention. Sexually Transmitted Disease
360 Surveillance 2021. 2023; <https://www.cdc.gov/std/statistics/2021/default.htm>.
361 Accessed May 23, 2023.
- 362 3. Gleason N, Banik S, Braverman J, Coleman E. The Impact of the COVID-19
363 Pandemic on Sexual Behaviors: Findings From a National Survey in the

- 364 United States. *J Sex Med.* 2021;18(11):1851-1862.
365 doi:10.1016/j.jsxm.2021.08.008
- 366 4. Twenge JM, Sherman RA, Wells BE. Declines in Sexual Frequency among
367 American Adults, 1989-2014. *Arch Sex Behav.* 2017;46(8):2389-2401.
368 doi:10.1007/s10508-017-0953-1
- 369 5. World Health Organization. Global progress report on HIV, viral hepatitis and
370 sexually transmitted infections, 2021.
371 <https://www.who.int/publications/i/item/9789240027077>. Accessed June 15,
372 2023.
- 373 6. Manhart LE, Gaydos CA, Taylor SN, et al. Characteristics of Mycoplasma
374 genitalium Urogenital Infections in a Diverse Patient Sample from the United
375 States: Results from the Aptima Mycoplasma genitalium Evaluation Study
376 (AMES). *J Clin Microbiol.* 2020;58(7). doi:10.1128/JCM.00165-20
- 377 7. Newman L, Rowley J, Vander Hoorn S, et al. Global Estimates of the
378 Prevalence and Incidence of Four Curable Sexually Transmitted Infections in
379 2012 Based on Systematic Review and Global Reporting. *PLoS One.*
380 2015;10(12):e0143304. doi:10.1371/journal.pone.0143304
- 381 8. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted
382 Infections Treatment Guidelines, 2021. *MMWR Recomm Rep.* 2021;70(4):1-
383 187. doi:10.15585/mmwr.rr7004a1
- 384 9. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. *Sex*
385 *Transm Infect.* 2013;89(6):426-433. doi:10.1136/sextrans-2012-051005
- 386 10. Muzny CA. Why Does *Trichomonas vaginalis* Continue to be a "Neglected"
387 Sexually Transmitted Infection? *Clin Infect Dis.* 2018;67(2):218-220.
388 doi:10.1093/cid/ciy085

- 389 11. Getman D, Jiang A, O'Donnell M, Cohen S. Mycoplasma genitalium
390 Prevalence, Coinfection, and Macrolide Antibiotic Resistance Frequency in a
391 Multicenter Clinical Study Cohort in the United States. *J Clin Microbiol.*
392 2016;54(9):2278-2283. doi:10.1128/JCM.01053-16
- 393 12. Sethi S, Zaman K, Jain N. Mycoplasma genitalium infections: current
394 treatment options and resistance issues. *Infect Drug Resist.* 2017;10:283-292.
395 doi:10.2147/IDR.S105469
- 396 13. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections:
397 gonorrhoea and Mycoplasma genitalium. *Nat Rev Urol.* 2017;14(3):139-152.
398 doi:10.1038/nrurol.2016.268
- 399 14. Recommendations for the laboratory-based detection of Chlamydia
400 trachomatis and Neisseria gonorrhoeae--2014. *MMWR Recomm Rep.*
401 2014;63(Rr-02):1-19.
- 402 15. Nelson HD, Zakher B, Cantor A, Deagas M, Pappas M. *Screening for*
403 *Gonorrhea and Chlamydia: Systematic Review to Update the U.S. Preventive*
404 *Services Task Force Recommendations.* Rockville (MD)2014.
- 405 16. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit
406 of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis
407 among men and women attending a sexually transmitted diseases clinic. *Clin*
408 *Infect Dis.* 2014;59(6):834-841. doi:10.1093/cid/ciu446
- 409 17. Muzny CA, Burkholder GA, Fry KR, Austin EL, Schwebke JR. Trichomonas
410 vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic. *Sex*
411 *Transm Dis.* 2016;43(8):483-488. doi:10.1097/OLQ.0000000000000479
- 412 18. Abbott Molecular. Alinity m STI AMP Kit [Package Insert]; 2018.

- 413 19. Chan PA, Robinette A, Montgomery M, et al. Extragenital Infections Caused
414 by *Chlamydia trachomatis* and *Neisseria gonorrhoeae*: A Review of the
415 Literature. *Infect Dis Obstet Gynecol*. 2016;2016:5758387.
416 doi:10.1155/2016/5758387
- 417 20. Herrmann B, Malm K. Comparison between Abbott m2000 RealTime and
418 Alinity m STI systems for detection of *Chlamydia trachomatis*, *Neisseria*
419 *gonorrhoeae*, and *Mycoplasma genitalium*. *Eur J Clin Microbiol Infect Dis*.
420 2021. doi:10.1007/s10096-020-04135-9
- 421 21. Obermeier M, Pacenti M, Ehret R, et al. Improved molecular laboratory
422 productivity by consolidation of testing on the new random-access analyzer
423 Alinity m. *Journal of Laboratory Medicine*. 2020;44(6):319-328.
424 doi:doi:10.1515/labmed-2020-0102
- 425 22. de Voux A, Bernstein KT, Kirkcaldy RD, Zlotorzynska M, Sanchez T. Self-
426 Reported Extragenital Chlamydia and Gonorrhea Testing in the Past 12
427 Months Among Men Who Have Sex with Men in the United States-American
428 Men's Internet Survey, 2017. *Sex Transm Dis*. 2019;46(9):563-570.
429 doi:10.1097/OLQ.0000000000001032
- 430 23. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea
431 and chlamydia reinfection is associated with increased risk of HIV
432 seroconversion. *J Acquir Immune Defic Syndr*. 2010;53(4):537-543.
433 doi:10.1097/QAI.0b013e3181c3ef29
- 434 24. Huppert JS, Reed JL, Munafo JK, et al. Improving notification of sexually
435 transmitted infections: a quality improvement project and planned experiment.
436 *Pediatrics*. 2012;130(2):e415-422. doi:10.1542/peds.2011-3326
437

438 **Figure Legends**

439

440 **Figure 1.** Stratification of specimen types included in the clinical comparative study.

441

442

443

444 **Tables**

445

446 **Table 1.** Final Observed Sensitivity of the Alinity m STI Assay

Pathogen	Target Concentration (Copies/mL)	Conversion Calculation Units	Average CN	High CN	Low CN	Reps Detected
CT	5	0.0023 EB/mL	36.54	37.86	34.56	10 / 10
NG	50	0.5 CFU/mL	37.97	39.94	36.69	10 / 10
TV	50	7.6E-5 TV/mL	30.33	31.16	27.36	10 / 10
MG	900	237 GE/mL	37.62	39.8	35.74	10 / 10

CFU, colony forming unit; CN, cycle number; CT, Chlamydia trachomatis; EB, elementary bodies; GE, genome equivalents; MG, Mycoplasma genitalium; NG, Neisseria gonorrhoea; TV, Trichomonas vaginalis.

447

448

449 **Table 2. Clinical Sample Agreement**

Rectal CT		M2000		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	6	0	95.0%	85.7%	100%
	NEG	1	13	(76.39,99.11)	(48.69,97.43)	(77.19,100.00)

Rectal NG		M2000		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	5	0	100%	100.0%	100.0%
	NEG	0	13	(82.41,100.00)	(56.55,100.00)	(77.19,100.00)

Oral CT		M2000		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	0	0	100.0%	.	100.0%
	NEG	0	13	(77.19,100.00)	(66.69,98.63)	(77.19,100.00)

Oral NG		M2000		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	4	0	92.3%	80%	100.0%
	NEG	1	8	(66.69,98.63)	(37.55,96.38)	(67.56,100.00)

Urine CT		M2000		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	13	0	100.0%	100.0%	100.0%
	NEG	0	174	(97.99,100.00)	(77.19,100.00)	(97.84,100.00)

Urine NG		M2000		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	10	1	99.5%	100.0%	99.4%
	NEG	0	176	(97.03,99.91)	(72.25,100.0)	(96.87,99.90)

Urine TV		Aptima		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	9	0	100.0%	100.0%	100.0%
	NEG	0	177	(97.98,100.00)	(70.09,100.00)	(97.88,100.00)

Urine MG		SureSwab		OPA	PPA	NPA
		POS	NEG			
Alinity m	POS	21	0	100.0%	100.0%	100.0%
	NEG	0	166	(97.99,100.00)	(84.54,100.00)	(97.74,100.00)

CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhoea; NPA, negative percent agreement; OPA, overall percent agreement; PPA, positive percent agreement; TV, Trichomonas vaginalis.

450 **Table 3.** Alinity m STI Assay Results by Clinical Specimen Type

Clinical Specimen Source	Total Tested	CT+	NG+	TV+	MG+
Male Urine	143	12	11	7	18
Female Urine	44	1	0	2	3
Rectal	20	7	6	0	1
Oropharyngeal	13	0	4	0	0
Endocervical / Vaginal	11	0	1	0	1
ThinPrep PreservCyt	29	0	0	0	0
Total	260	25	27	11	23


CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhoea; TV, Trichomonas vaginalis.

451

453 **Figures**

454

455 **Figure 1.** Stratification of specimen types included in the clinical comparative study.



456

457

458 Supplemental

459 **Table s1.** Observed Sensitivity Range-Finding Results for the Alinity m STI Assay

Pathogen	Levels Tested (Copies / mL)	Average CN	Reps Detected
CT	300	35.54	3 / 3
	150	35.5	3 / 3
	75	35.96	3 / 3
	20	37.45	3 / 3
	10	37.7	3 / 3
	5	38.59	2 / 3
NG	500	32.51	3 / 3
	250	33.98	3 / 3
	100	35.45	3 / 3
	50	37.00	3 / 3
	40	37.93	2 / 3
TV	150	32.00	3 / 3
	75	31.85	3 / 3
	50	31.42	3 / 3
	25	N / D	0 / 3
	10	N / D	0 / 3
MG	1700	28.53	3 / 3
	1500	29.27	3 / 3
	1000	30.37	3 / 3
	900	29.57	0 / 3
	750	38.95	2 / 3

CN, cycle number; CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhoea; TV, Trichomonas vaginalis.

460

461 **Table s2.** Neat Urine Stability Summary

Pathogen	CT		NG		TV		MG	
Baseline CN	27.78		24.5		21.75		27.24	
	-20°C	4°C	-20°C	4°C	-20°C	4°C	-20°C	4°C
Day 1 CN	27.49	27.62	24	26.49	23.61	22.42	27.75	27.23
Day 3 CN	27.96	27.75	24.25	27.13	25.1	23.37	28.69	27.55
Day 5 CN	27.36	27.62	25.24	27.63	24.42	24.89	27.86	26.99
Day 7 CN	27.62	27.29	25.57	27.43	26.73	25.82	28.86	27.5
Average CN	27.61	27.57	24.77	27.17	24.97	24.13	28.29	27.32
SD	0.26	0.20	0.76	0.50	1.32	1.52	0.57	0.26
2 SD	0.52	0.39	1.52	1.00	2.65	3.04	1.13	0.52

CFU, colony forming unit; CN, cycle number; CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhoea; SD, standard deviation; TV, Trichomonas vaginalis.

462

463